Targeted therapy shows benefit for people with advanced breast cancer in late-stage trial
An experimental treatment shows promise for people with the most common form of advanced-stage breast cancer, according to results from a Phase 3 clinical trial.
The details of the trial were presented Thursday at the San Antonio Breast Cancer Symposium. It showed that AstraZeneca’s capivasertib – in combination with Faslodex (fulvestrant), an endocrine therapy already used to treat advanced breast cancer – gave people a median of 7.2 months without disease progression, compared with 3.6 months in people who got a placebo plus the endocrine therapy.
